Health Care • Biotechnology: Pharmaceutical Preparations
$0.37 ▼ -0.01
(-1.53%)
MKT CAP: $1.7M • VOL: 6.4K
52W L $0 52W H $1
ROARABLE / RQD
D • 44/100
PIOTROSKI
2 / 9
OGEN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $37.7K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$9.4M | -$10.6M | -$20.9M |
| Operating Margin % | — | — | -80.0% |
| Net Income (GAAP) | -$984.2M | -$1.06B | -$20.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.2M | -$8.6M | -$7.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$9.2M | -$8.6M | -$7.3M |
| FCF Margin % | — | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.4M | $864.8K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $8.3M | -$211.9K | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OGEN.